Scientists have previously focused on the characteristics of the directional migration of MSCs to tumor sites and their application value in tumor-targeted therapy, as researchers found that human bone marrow-derived MSCs genetically engineered with IFN-β preferentially incorporate into melanomas in the lungs rather than the natural lung parenchyma and into subcutaneous melanomas rather than other normal organs, such as the liver, after intravenous injection and locally secrete IFN-β to inhibit melanoma growth [84]. The gene discussed is IFNB1; the disease is melanoma.